When treating Alzheimer’s, earlier is better, according to analysis of Lilly and Eisai trials
The drugmakers behind the new class of Alzheimer’s treatments are coalescing around a common narrative: When it comes to slowing the disease, the earlier a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.